NextCure, Inc.
Nasdaq NXTC · Baltimore, MD
Works in Dermatology · GI & liver · Hematology · Metabolic & endocrine · Oncology · Renal & urogenital · Respiratory · Women's health
NextCure, Inc. is a clinical trial sponsor based in Baltimore, MD, listed as Nasdaq NXTC. It has 2 active clinical trials with 883 planned participants, across 8 therapeutic areas. Since 2021 it has completed 1 trial and stopped 5 early.
Trial track record · since 2021
Financials · Nasdaq NXTC
Fundraising
Pipeline · 2 active trials
| Stage | Trial | Status |
|---|---|---|
Questions about NextCure, Inc
NextCure, Inc is lead sponsor of 2 active clinical trials on ClinicalTrials.gov, with 883 planned participants, in Dermatology, GI & liver, Hematology, Metabolic & endocrine and other areas. Since 2021 it has completed 1 trial and stopped 5 early.
NextCure, Inc is based in Baltimore, MD and is listed as Nasdaq NXTC. The address is the one on its SEC filings, which name the establishment or the registrant, not always the group's head office.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with NextCure, Inc; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-08-21.
Approve Suite is not affiliated with NextCure, Inc..
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.